Here's a copy/paste of my NWBO patent cheat sheet that I try to keep up to date with the latest patent office actions. Status first, then any recent actions and date of the action, USPTO file number that can be used to look up the record in Patent Center, and the name. Please correct me if I've left any out. Most exciting recent action of late is the notice of allowance recently received for the second one in the list.
IN PROGRESS (non-final rejection 9-7-23) 20220145246 OPTIMALLY ACTIVATED DENDRITIC CELLS THAT INDUCE AN IMPROVED OR INCREASED ANTI-TUMOR IMMUNE RESPONSE
IN PROGRESS (notice of allowance received 7-20-23) 20210102169 GENERATION OF DENDRITIC CELLS FROM MONOCYTIC DENDRITIC PRECURSOR CELLS WITH GM-CSF IN THE ABSENCE OF ADDITIONAL CYTOKINES
IN PROGRESS (request for continued examination 7-3-23) 20190046568 METHODS RELATING TO ACTIVATED DENDRITIC CELL COMPOSITIONS AND IMMUNOTHERAPEUTIC TREATMENTS FOR SUBJECTS WITH ADVANCED CANCERS
PATENTED 20180187145 OPTIMALLY ACTIVATED DENDRITIC CELLS THAT INDUCE AN IMPROVED OR INCREASED ANTI-TUMOR IMMUNE RESPONSE
ABANDONED (7-8-22) 20170363625 QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS
PATENTED 20160024472 Generation of Dendritic Cells from Monocytic Dendritic Precursor Cells with GM-CSF in the Absence of Additional Cytokines
IN PROGRESS (notice of appeal filed 8-23-23) 20150273033 COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER
IN PROGRESS (notice of appeal filed 3-20-23) 20150202291 COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER
PATENTED 20140072564 THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS
PATENTED 20130273654 Generation of Dendritic Cells from Monocytic Dendritic Precursor Cells with GM-CSF in the Absence of Additional Cytokines
ABANDONED 20130017600 ISOLATION AND/OR PRESERVATION OF DENDRITIC CELLS FOR PROSTATE CANCER IMMUNOTHERAPY
ABANDONED (7/6/17, non-timely payment) 20120252034 QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS
IN PROGRESS (final rejection 8-24-23) 20120251561 ADMINISTRATION OF DENDRITIC CELLS PARTIALLY MATURED IN VITRO FOR THE TREATMENT OF TUMORS
IN PROGRESS (non-final rejection 9-6-23) 20120244620 COMPOSITIONS AND METHODS FOR INDUCING THE ACTIVATION OF IMMATURE MONOCYTIC DENDRITIC CELLS
PATENTED 20110189150 TANGENTIAL FLOW FILTRATION DEVICES AND METHODS FOR LEUKOCYTE ENRICHMENT
EXPIRED (non-payment 4-28-17) 20100062003 THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BASED ON THE ROLE OF THE CXCR-4 GENE IN TUMORIGENESIS
ABANDONED 20100008892 QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS
ABANDONED 20080254537 Compositions and Methods for Inducing the Activation of Immature Monocytic Dendritic Cells
ABANDONED (12-13-22) 20080254064 COMPOSITIONS AND METHODS FOR PRIMING MONOCYTIC DENDRITIC CELLS AND T CELLS FOR TH-1 RESPONSE
ABANDONED (9/21/17) 20080171023 METHOD TO INCREASE CLASS I PRESENTATION OF EXOGENOUS ANTIGENS BY HUMAN DENDRITIC CELLS
PATENTED 20070004655 NR-CAM GENE, NUCLEIC ACIDS AND NUCLEIC ACID PRODUCTS FOR THERAPEUTIC AND DIAGNOSTIC USES FOR TUMORS
ABANDONED 20060234309 Quality assays for antigen presenting cells
ABANDONED 20060234286 HUMAN PARIS-1 ANTIGEN AND NUCLEIC ACIDS: DIAGNOSTIC AND THERAPEUTIC USES
ABANDONED 20060057120 Administration of dendritic cells partially matured in vitro for the treatment of tumors
ABANDONED 20050202019 Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
ABANDONED 20050059151 Compositions and methods for priming monocytic dendritic cells and t cells for th-1response
PATENTED 20050189297 Tangential flow filtration devices and methods for stem cell enrichment
PATENTED 20050173315 Tangential flow filtration devices and methods for leukocyte enrichment
PATENTED 20040203143 Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines
PATENTED 20040197903 Method for induction of proliferation of natural killer cells by dendritic cells cultured with GM-CSF and IL-15
EXPIRED (non-payment 5-13-19) 20040024188 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
